The Utility of Sentinel Lymph Node Biopsy in Elderly Patients with Melanoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Sentinel lymph node biopsy (SLNB) improves survival for elderly melanoma patients. Age alone should not preclude SLNB, as reduced performance may indicate missed treatment opportunities.
Area Of Science
- Oncology
- Surgical Oncology
- Geriatric Medicine
Background
- Sentinel lymph node biopsy (SLNB) is underutilized in elderly melanoma patients.
- Investigating the impact of SLNB on melanoma-specific survival (MSS) in older individuals is crucial.
Purpose Of The Study
- To determine the association between SLNB and MSS in patients aged 70 years and older with melanoma.
- To analyze factors influencing SLNB performance in this demographic.
Main Methods
- Retrospective review of the SEER database (2010-2019) for patients aged ≥70 with cT2-4N0M0 melanoma.
- Multivariable Cox proportional hazard and logistic regression models were used to assess SLNB impact on MSS and performance, respectively.
Main Results
- SLNB was performed in 58.5% of 11,548 patients; 15.5% had a positive result.
- A negative SLN was linked to improved MSS up to age 87 (HR 0.59).
- Positive SLNB was associated with inferior MSS (HR 1.71), and SLNB performance decreased with increasing age.
Conclusions
- SLNB is associated with improved cancer-specific survival and provides prognostic value in elderly melanoma patients.
- Age alone should not be a reason to withhold SLNB; clinical judgment regarding performance status and patient preference is key.
- Declining SLNB rates in older patients may represent a missed opportunity for potentially curative treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.